Compare Regeneron Pharmaceuticals Inc (REGN) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Global X SuperDividend ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Global X SuperDividend ETF trades at $24.98. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Global X SuperDividend ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| REGN | SDIV | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $852.03 | $26.34 |
52-Week Low | $555.51 | $22.90 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
SDIV trades at $25.07, down 0.16% with a bullish technical signal from moving averages. The ETF maintains a consistent $0.18 monthly dividend payment schedule through mid-2026, providing income stability. Recent news highlights SDIV's 9.29% yield and diversification benefits away from tech-heavy portfolios, though questions remain about dividend sustainability.
The outlook balances high income generation against sustainability concerns. Key opportunities include attractive yield in a low-rate environment and non-tech diversification, while risks center on dividend coverage and sensitivity to global economic conditions. Technical strength supports near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
